The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients
Open accessAbstract
Introduction: Epithelial to mesenchymal transition (EMT) is considered an essential process in the metastatic cascade. EMT is characterised by upregulation of vimentin, Twist, Snail, Slug and Sip1 among others. Metastasis is also associated with the presence of circulating tumour cells (CTCs) and disseminated tumour cells in the blood and bone marrow, respectively, of breast cancer patients, but the expression of EMT markers in these cells has not been reported so far. Methods: The expression of Twist and vimentin in CTCs of 25 metastatic and 25 early breast cancer patients was investigated by using double-immunofluorescence experiments in isolated peripheral blood mononuclear cell cytospins using anti-cytokeratin (anti-CK) anti-mouse (A45-B/B3) and anti-Twist or anti-vimentin anti-rabbit antibodies. Results: Among early breast cancer patients, vimentin-and Twist-expressing CK+ CTCs were identified in 77% and 73% of the patients, respectively, and in 100% of the patients with metastatic breast cancer for both markers (P = 0.004 and P = 0.037, respectively). Among patients with early disease, 56% and 53% of the CK+ CTCs were double-stained with vimentin and Twist, and the corresponding values for metastatic patients were 74% and 97%, respectively (P = 0.005 and P = 0.0001, respectively). The median expression of CK+vimentin+ and CK+Twist+ cells per patient in metastatic patients was 98% and 100%, and in an adjuvant chemotherapy setting the corresponding numbers were 56% and 40.6%, respectively. Triple-staining experiments revealed that all CK+Twist+ or CK+vimentin+ cells were also CD45-, confirming their epithelial origin. Immunomagnetic separation of CTCs and triple-immunofluorescence with anti-CK/anti-Twist/anti-vimentin antibodies demonstrated that both mesenchymal markers could be coexpressed in the same CK+ cell, since 64% of the total identified CTCs were triple-stained. There was a significant correlation (P = 0.005) between the number of CTCs expressing Twist and vimentin within the same setting. Conclusions: CTCs expressing Twist and vimentin, suggestive of EMT, are identified in patients with breast cancer. The high incidence of these cells in patients with metastatic disease compared to early stage breast cancer strongly supports the notion that EMT is involved in the metastatic potential of CTCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,855
Cano, A., Pérez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F., & Nieto, M. A. (2000) · Nature Cell Biology · doi:10.1038/35000025 · Cited by 3,668
Direct regulation of TWIST by HIF-1α promotes metastasis
Yang, M.-H., Wu, M.-Z., Chiou, S.-H., Chen, P.-M., Chang, S.-Y., Liu, C.-J., Teng, S.-C., & Wu, K.-J. (2008) · Nature Cell Biology · doi:10.1038/ncb1691 · Cited by 1,345
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., Doyle, G. V., Matera, J., Allard, W. J., Miller, M. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.140 · Cited by 1,135
Circulating Tumor Cells in Patients with Breast Cancer Dormancy
Meng, S., Tripathy, D., Frenkel, E. P., Shete, S., Naftalis, E. Z., Huth, J. F., Beitsch, P. D., Leitch, M., Hoover, S., Euhus, D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1110 · Cited by 971
Circulating tumor cells (CTC) detection: Clinical impact and future directions
Paterlini-Brechot, P., & Benali, N. L. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.014 · Cited by 947
Aktas, B., Tewes, M., Fehm, T., Hauch, S., Kimmig, R., & Kasimir-Bauer, S. (2009) · Breast Cancer Research · doi:10.1186/bcr2333 · Cited by 736
Rosivatz, E., Becker, I., Specht, K., Fricke, E., Luber, B., Busch, R., Höfler, H., & Becker, K.-F. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64464-1 · Cited by 572
Cheng, G. Z., Chan, J., Wang, Q., Zhang, W., Sun, C. D., & Wang, L.-H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1479 · Cited by 546
Cited by
Epithelial–mesenchymal plasticity in carcinoma metastasis
Tsai, J. H., & Yang, J. (2013) · Genes & Development · doi:10.1101/gad.225334.113 · Cited by 1,136
Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S., & Yang, J. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.022 · Cited by 1,071
Circulating tumor cells: biology and clinical significance
Lin, D., Shen, L., Luo, M., Zhang, K., Li, J., Yang, Q., Zhu, F., Zhou, D., Zheng, S., Chen, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00817-8 · Cited by 993
Epithelial–mesenchymal transition in tumor metastasis
Yeung, K. T., & Yang, J. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12017 · Cited by 723
Molecular analysis of circulating tumour cells—biology and biomarkers
Krebs, M. G., Metcalf, R. L., Carter, L., Brady, G., Blackhall, F. H., & Dive, C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.253 · Cited by 622
Gorges, T. M., Tinhofer, I., Drosch, M., Röse, L., Zollner, T. M., Krahn, T., & von Ahsen, O. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-178 · Cited by 565
Epithelial–mesenchymal transition (EMT) and metastasis: yes, no, maybe?
Diepenbruck, M., & Christofori, G. (2016) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2016.06.002 · Cited by 475
EMT, CTCs and CSCs in tumor relapse and drug-resistance
Mitra, A., Mishra, L., & Li, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4037 · Cited by 465
Eccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., Berditchevski, F., Blaydes, J. P., Brennan, K., Brown, N. J., Bryant, H. E., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3493 · Cited by 421
Ignatiadis, M., Lee, M., & Jeffrey, S. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1190 · Cited by 355
Marino, N., Woditschka, S., Reed, L. T., Nakayama, J., Mayer, M., Wetzel, M., & Steeg, P. S. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.06.012 · Cited by 309
Classification of Circulating Tumor Cells by Epithelial-Mesenchymal Transition Markers
Wu, S., Liu, S., Liu, Z., Huang, J., Pu, X., Li, J., Yang, D., Deng, H., Yang, N., & Xu, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123976 · Cited by 282
Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation
Salt, M. B., Bandyopadhyay, S., & McCormick, F. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0520 · Cited by 124
Kim, J. H., Verwilst, P., Won, M., Lee, J., Sessler, J. L., Han, J., & Kim, J. S. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03875 · Cited by 98
Metadata
- Authors
- Kallergi, G., Papadaki, M. A., Politaki, E., Mavroudis, D., Georgoulias, V., & Agelaki, S.
- Venue
- Breast Cancer Research
- Published
- 2011-06
- Volume
- 13
- Issue
- 3
- Pages
- R59-R59
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2103736766
- Cited by
- 377
- References
- 47
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.